[Form 4] MiNK Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Ulf Wiinberg, a director of MiNK Therapeutics, Inc. (INKT), reported a grant and his current holdings. On 09/02/2025 Mr. Wiinberg was granted 1,011 restricted stock units (RSUs) received in lieu of cash board and committee retainers; the RSUs vest one month from the grant date and are valued at $13.86 per share on the filing. Following the grant he beneficially owns 18,971 shares directly and 27,830 shares indirectly held in an irrevocable trust for his family.

Positive

• Director received equity compensation (1,011 RSUs) which aligns his interests with shareholders
• Clear disclosure of holdings: 18,971 shares directly owned and 27,830 shares held in an irrevocable family trust

Negative

• None.

Insights

Financial Analyst

TL;DR: Director received short‑term RSUs as compensation, modestly increasing his direct stake; not a material change to cap table for investors.

The Form 4 shows a director compensation grant of 1,011 RSUs at an indicated price of $13.86, vesting in one month. This replaces cash retainers and aligns director pay with equity incentives. The filing also discloses existing holdings of 18,971 direct shares and 27,830 shares held indirectly in an irrevocable family trust. The absolute sizes reported are small relative to typical public company float and thus unlikely to move market valuation by themselves; they do, however, signal routine governance alignment via equity compensation.

Corporate Governance Expert

TL;DR: Routine director equity compensation and disclosure; trust holding indicates standard estate/ownership planning, not a change in control.

The disclosure is a standard Section 16 filing for director compensation paid in RSUs that vest after one month. The presence of an irrevocable trust holding 27,830 shares is explicitly noted and clarifies indirect beneficial ownership. No departures, option grants with unusual terms, or rapid sale activity are reported. From a governance perspective this is a routine update consistent with aligning board members with shareholder interests via equity-based pay.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WIINBERG ULF

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		A		1,011	A	$13.86(1)	18,971	D
Common Stock								27,830(2)	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.

2. Shares are held in an irrevocable trust for the benefit of Mr. Wiinberg's family.

	By: /s/ Christine Klaskin, Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Ulf Wiinberg report on Form 4 for INKT?

The Form 4 reports a grant of 1,011 RSUs on 09/02/2025, received in lieu of cash retainers for board and committee compensation.

When do the RSUs granted to the director vest?

The RSUs will vest one month from the grant date, per the filing.

How many INKT shares does Ulf Wiinberg beneficially own after the reported transaction?

He beneficially owns 18,971 shares directly and 27,830 shares indirectly held in an irrevocable trust for his family.

What price is shown on the Form 4 for the RSU grant?

The filing indicates a price of $13.86 per share associated with the RSU grant.

Who signed the Form 4 filing for Ulf Wiinberg?

The Form 4 was signed by Christine Klaskin, Attorney-in-Fact on 09/03/2025.